Live
- Centre’s intent is to finish off small parties: DK Shivakumar
- Allu Arjun Released from Chanchalguda Jail, says he respects law
- Jesus is synonymous with sacrifice, forgiveness: Ponnam
- HC announces verdict in Kannada for the first time
- Uttam releases water from Nizam Sagar for Rabi crop
- TG to be Rs 84L cr economy in 10 years: Sridhar Babu
- First TGCHE, V-Cs meet deliberates on higher education roadmap for state
- 2 senior professors to join NALSAR
- Former Principal of SPW College passes away in US
- Hyderabad: Govt out to remove electric poles, transformers on roads across city
India’s IPR stance promotes affordable medicines: GTRI
New Delhi: India’s stand on intellectual property rights (IPRs) and pharma issues in proposed trade agreements balances innovation with public health...
New Delhi: India’s stand on intellectual property rights (IPRs) and pharma issues in proposed trade agreements balances innovation with public health needs, ensures availability of affordable medicines and promotes growth of generic medicine industry, a GTRI report said on Friday.
Think tank Global Trade Research Initiative (GTRI) said that by opposing demands of developed nations on issues like ‘data exclusivity’ and ‘patent linkage’ in free trade agreements (FTAs), India ensures that generic drug manufacturers get greater market access and cost of life-saving medicines gets reduced significantly.
“India’s approach underscores a commitment to balancing innovation with public health needs, adopting a flexible interpretation of TRIPS to align with its developmental goals, and preventing the establishment of unfair monopolies, especially in the pharmaceutical sector,” the GTRI paper said.
